Gemcitabine plus pembrolizumab after checkpoint blockade failure as a strategy in multiply relapsed Hodgkin lymphoma. Article uri icon

Overview

publication date

  • October 31, 2023

Research

keywords

  • Hodgkin Disease
  • Lymphoma, Non-Hodgkin

Identity

PubMed Central ID

  • PMC10932868

Scopus Document Identifier

  • 85175492094

Digital Object Identifier (DOI)

  • 10.1111/bjh.19178

PubMed ID

  • 37905372

Additional Document Info

volume

  • 204

issue

  • 2